- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 6, 2024
Distillery Therapeutics
Increasing podocyte OTUD5 activity for diabetic kidney disease
BioCentury | Feb 18, 2023
Regulation
Feb. 17 Quick Takes: Apellis’ Syfovre first to market for geographic atrophy
Plus: Amid partnership talks, Madrigal also ‘open’ to M&A; and updates from Panakès, Aqilion-Merck KGaA, Pfizer, Merck & Co.
BioCentury | Jun 26, 2020
Distillery Therapeutics
MAP3K7, IL18R1 as targets in obesity-related cerebrovascular dysfunction
BioCentury | May 26, 2020
Distillery Therapeutics
Boosting Tnip3-mediated inhibition of MAP3K7 for non-alcoholic steatohepatitis
BioCentury | Aug 31, 2017
Targets & Mechanisms
Necroptosis strikes again
Direct evidence of necroptosis in Alzheimer's
Items per page:
1 - 10 of 17